Carlsmed, a spine medtech company, launched its initial public offering of 6.7 million shares of common stock, according to a June 15 news release.
Common stock price is expected to be between $14 and $16 per share, and the company applied to be listed on the Nasdaq Global Select Market.
Carlsmed is behind aprevo personalized spine implants. The company filed for the IPO in June, and BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler are the joint lead book-running managers and representatives.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
